CONNECTIVINA * 10GARZE 2MG 10x10

CONNECTIVINA * 10GARZE 2MG 10x10

Therapeutic indications

Treatment of abrasions, bruises, superficial wounds, burns, minor burns and breast fissures. Treatment of localized skin irritations caused by physical agents such as sun, cold, wind, diaper rash, irritation and dehydration resulting from radiotherapy treatments. Adjuvant treatment of skin ulcers of vascular origin and slow-healing wounds such as bedsores.

Dosage and method of use

CONNETTIVINA 2 mg / ml Cutaneous spray, solution: 2–3 applications per day, evenly covering the entire affected area. CONNETTIVINA 2 mg Impregnated gauze, CONNETTIVINA 4 mg Impregnated gauze and CONNETTIVINA 12 mg Impregnated gauze: apply 1 or more impregnated gauze depending on the extent of the area to be treated, changing it / s 2-3 times a day. If necessary, cover the dressing with a suitable bandage. Before applying CONNETTIVINA spray and gauze, the wounds deriving from vascular ulcers and bedsores must be cleaned preferably with physiological solution (NaCl 0.9%); if necessary, surgical cleaning should be performed. Subsequently, the wounds should preferably be disinfected with povidone iodine or chlorhexidine. Quaternary ammonium solutions tend to precipitate hyaluronic acid and should therefore be avoided. After applying the dressing, cover, if necessary, with a suitable bandage.

Contraindications

Hypersensitivity to the active substance and other chemically closely related substances or to any of the excipients listed in section 6.1.

Side effects

Following the application of CONNETTIVINA, local reactions, including allergic ones, were recorded. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http://www.agenziafarmaco.gov.it/it/responsabili.

Special warnings

The use of the product, especially if prolonged, can give rise to sensitization phenomena. If this happens, treatment must be discontinued and appropriate therapy instituted.

Pregnancy and breastfeeding

The drug can be used during pregnancy and breastfeeding.

Expiration and retention

Skin spray, solution and impregnated gauzes: do not store above 30 ° C.

Interactions with other drugs

The association of hyaluronic acid with antibiotics and other local treatments has never given rise to interaction phenomena. Do not use simultaneously with disinfectants containing quaternary ammonium salts as hyaluronic acid can precipitate in their presence.

Overdose

There are no known cases of connettivina overdose.

Active principles

CONNETTIVINA 2mg / ml Cutaneous spray, solution: 1 ml contains 2 mg of hyaluronic acid sodium salt. Excipients with known effects: methyl p – hydroxybenzoate and propyl p – hydroxybenzoate. CONNETTIVINA 2 mg Impregnated gauze: a 10x10 cm gauze is impregnated with 4 g of cream containing 2 mg of hyaluronic acid sodium salt. CONNETTIVINA 4 mg Impregnated gauze: a 10x20 cm gauze is impregnated with 8 g of cream containing 4 mg of hyaluronic acid sodium salt. CONNETTIVINA 12 mg Impregnated gauze: a 20x30 cm gauze is impregnated with 24 g of cream containing 12 mg of Hyaluronic acid sodium salt Excipient with known effects: polyethylene glycol 4000. For the complete list of excipients, see section 6.1

Excipients

CONNETTIVINA 2 mg / ml Cutaneous spray, solution Sodium chloride - methyl p-hydroxybenzoate - propyl p-hydroxybenzoate - purified water CONNETTIVINA 2 mg Impregnated gauze, CONNETTIVINA 4 mg Impregnated gauze, CONNETTIVINA 12 mg Impregnated gauze Glycerol - polyethylene glycol 4000 - purified water